10-Q: Ainos Reports Q2 2026 Results: Revenue Plummets, Losses Widen

Ainos, Inc. reported a substantial decrease in revenue and a widening net loss for the second quarter of 2026, primarily due to a strategic shift away from VELDONA pet supplements towards its AI Nose platform, which is still in early commercialization stages.

Summary

• Ainos, Inc. reported a significant decline in revenue for the second quarter and first half of 2026, with Q2 revenue dropping 97% to $152 and H1 revenue falling 100% to $313 compared to the prior year periods.
• The company experienced a substantial increase in operating losses, with Q2 2026 operating loss at $4.4 million (up 17% from Q2 2025) and H1 2026 operating loss at $6.7 million (down 3% from H1 2025, but still substantial).
• Net loss for Q2 2026 was $4.6 million, an increase of 12% from Q2 2025, and for H1 2026 was $7.1 million, a decrease of 4% from H1 2025.
• The company's cash and cash equivalents increased to $1.42 million as of June 30, 2026, from $417,353 as of December 31, 2025, largely due to financing activities.
• Despite increased cash, substantial doubt exists about the company's ability to continue as a going concern due to ongoing net operating losses and an accumulated deficit of $74.6 million as of June 30, 2026.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as negative due to significant revenue decline, increasing operating losses, and continued concerns about the company's ability to continue as a going concern, despite some progress in AI Nose development.

Positives

• Cash and cash equivalents increased to $1,422,912 as of June 30, 2026, from $417,353 as of December 31, 2025, providing more operational runway.
• Net loss for the first half of 2026 decreased by 4% to $7,054,531 compared to $7,371,012 in the first half of 2025.
• Operating loss for the first half of 2026 decreased by 3% to $6,682,733 compared to $6,908,558 in the first half of 2025.
• The company continues to advance its AI Nose platform development and commercialization efforts, particularly in industrial applications like semiconductor manufacturing and robotics.
• A new loan agreement with ASE Test, Inc. provided $2.8 million in funding, and the maturity date for a portion of this loan was extended.

Negatives

• Revenue for Q2 2026 plummeted by 97% to $152 compared to $4,663 in Q2 2025, and H1 2026 revenue dropped 100% to $313 compared to $110,870 in H1 2025.
• Gross profit for Q2 2026 was $99, a 97% decrease from $3,726 in Q2 2025, and H1 2026 reported a gross loss of $503 compared to a gross profit of $91,700 in H1 2025.
• Operating expenses increased by 17% in Q2 2026 to $4.4 million, driven by a 39% increase in SG&A expenses.
• Net loss for Q2 2026 increased by 12% to $4.6 million compared to $4.1 million in Q2 2025.
• The company has an accumulated deficit of $74,574,859 as of June 30, 2026, and management acknowledges substantial doubt about its ability to continue as a going concern.
• The company is shifting focus from VELDONA pet supplements to AI Nose, leading to significantly lower current revenues from the former.

Risks

• Substantial doubt exists about the company's ability to continue as a going concern due to ongoing net operating losses and an accumulated deficit.
• The company's ability to meet its obligations is dependent on generating sufficient cash flows from operations and future financing transactions, which are not assured.
• Fluctuating foreign currency and exchange rates may negatively impact the company's business, results of operations, and financial position.
• Policy changes affecting international trade could adversely impact demand for products and the company's competitive position.
• Component supply and manufacturing disruptions could increase costs and delay customer deployments.
• The timing and extent of partner execution, customer adoption, and conversion of pilot activities into broader commercial arrangements may affect revenue and near-term operating results.
• The company continues to develop AI Nose for near-threshold detection scenarios, which requires ongoing validation for reliability, repeatability, and scalability.

Future Outlook

The company anticipates continued investment in product development and clinical trial activities to advance its pipeline. It expects to fund operations over the next twelve months through cash reserves, business revenues, and potential debt financing. However, there is no assurance of profitability or successful fundraising, and the company may need to reevaluate its operating plan if financing is not available.

Management Comments

• The Company may adjust the timing, scope, and prioritization of these activities based on available capital, regulatory developments, market conditions, partner execution, and other factors.
• We expect that our R&D investments may continue to grow as we further develop our technologies.
• We continued to invest resources to execute our growth strategy and product roadmap to improve our profitability.
• The Company anticipates that cash reserves, business revenues, and potential debt financing through convertible and non-convertible notes will fund the Companys operations over the next twelve months.
• There can be no assurance that we will be successful in our efforts to make the Company profitable.

Industry Context

StockSavvy.ai notes that Ainos operates in two distinct, high-potential but capital-intensive sectors: AI-driven olfactory sensing (SmellTech) and immune therapeutics. The current financial results reflect the challenges of commercializing novel technologies in these fields, particularly the AI Nose platform, which requires significant investment in R&D and market development. The shift in focus towards industrial applications for AI Nose, away from earlier healthcare-adjacent and consumer products, aligns with broader industry trends of leveraging AI for industrial automation and monitoring, but also indicates a longer path to revenue generation.

Comparison to Industry Standards

• The significant revenue decline and increasing operating losses are concerning when compared to companies in the AI and biotechnology sectors that are demonstrating consistent revenue growth and progress towards profitability.
• While many early-stage biotech and AI companies experience net losses, the magnitude of Ainos's accumulated deficit ($74.6 million) and the explicit statement of substantial doubt about its going concern status are red flags.
• Competitors in the AI sensing market are often backed by substantial venture capital or are part of larger corporations, allowing for sustained R&D and market penetration efforts, which Ainos may struggle to match given its current financing situation.
• In the immune therapeutics space, companies typically require significant clinical trial data and regulatory approvals to attract substantial investment, a process Ainos's VELDONA program is still navigating.

Legal Proceedings

• As of the date of this report, the company was not aware of any material legal proceedings involving the Company.

Related Party Transactions

• Product Co-development Agreement with Taiwan Carbon Nano Technology Corporation (TCNT) for development expenses and patent use fees.
• Manufacturing Service Agreement with TCNT for AI Nose hardware products.
• Lease agreement for office space in Taiwan with a director of the Company.

Stakeholder Impact

• Shareholders may experience continued dilution if the company raises capital through equity offerings.
• Shareholders face significant risk due to the company's going concern issues and potential for stock price decline.
• Creditors and noteholders face risk if the company cannot meet its debt obligations.
• Employees may face uncertainty regarding job security given the company's financial condition and need for future financing.

Next Steps

• Continue advancing AI Nose commercialization activities, with a focus on partner-led deployments and data refinement.
• Continue semiconductor deployment and validation efforts for AI Nose.
• Support AI Nose commercialization through channel and integration partners.
• Continue development of SLM and Smell ID datasets using deployment and pilot data.
• Continue robotics-related pilot and deployment activities for AI Nose.
• Continue evaluating healthcare-adjacent applications for AI Nose.
• Continue clinical activities for VELDONA in Taiwan, subject to progress and resources.
• Pursue partnering and out-licensing opportunities for VELDONA.

Key Dates

Recommendation

The filing indicates a severe decline in revenue, widening losses, and significant going concern risks. Despite progress in AI Nose development, the financial health and ability to continue operations are highly uncertain, making it a high-risk investment.

Keywords

AI Nose, SmellTech, Smell AI, olfactory sensing, immune therapeutics, VELDONA, semiconductor manufacturing, healthcare